Major histocompatibility complex, class II, DM beta chain (HLA-DMB)

Major histocompatibility complex, class II, DM beta chain (HLA-DMB) is a nonclassical MHC class II beta chain protein that forms a heterodimer with the DMA alpha chain. It plays a crucial intracellular role in facilitating the exchange of peptides on classical MHC class II molecules by catalyzing the release of the CLIP peptide, thereby regulating antigen presentation to CD4+ T cells in antigen-presenting cells (APCs) such as B lymphocytes, dendritic cells, and macrophages[1][2][3][4]. HLA-DMB is essential for the adaptive immune response, influencing the repertoire of peptides displayed by MHC class II molecules, and genetic or expression alterations in HLA-DMB can affect susceptibility to cancer, autoimmune disease, and infection. Elevated HLA-DMB expression in tumors often correlates with improved T-cell infiltration and better prognosis, suggesting value as an immune biomarker[1][2]. While not a direct therapeutic target, HLA-DMB function is central to the efficacy of immunotherapies dependent on intact antigen presentation machinery[2][3][4].

Other names

HLA class II histocompatibility antigen, DM beta chainDMBRING7D6S221EMHC class II antigen DMBReally interesting new gene 7 proteinMHC class II HLA-DMBMHC class II antigen HLA-DM beta chainClass II histocompatibility antigen, M beta chain

No drugs act directly; immunotherapies may rely on or be modulated by enhanced MHC class II antigen presentation via HLA-DMB[2][3].